Global anti-infective endotracheal tube market growth is driven by rising incidence of hospital acquired pneumonia (HAP). Anti-infective endotracheal tubes help prevent ventilator associated pneumonia, which affects millions of intubated patients worldwide each year and contributes substantially to patient morbidity, mortality and healthcare costs. These tubes have an antibacterial coating that reduces bacterial adhesion and biofilm formation in the lower respiratory tract, thus, helping curb the risk of pneumonia during ventilation. Their use in mechanically ventilated patients is becoming increasingly important as antibiotic resistance grows and standards of care evolve to mitigate an important cause of preventable harm.
Market Dynamics:
Global anti-infective endotracheal tube market growth is primarily driven by rising demand for technologies and solutions that enhance patient safety, reduce complications, and lower healthcare costs associated with hospital stays. Growing geriatric population who are more prone to critical illness can also drive the market growth. However, high costs associated with these specialty tubes compared to conventional tubes can hamper the market growth. Increasing investments by governments and payers to curb hospital acquired infections offer numerous lucrative growth opportunities. Ongoing R&D aimed at developing more effective coatings and designs can expand commercial scope for existing players.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook